Beixian Life (688712.SH) has disclosed its prospectus, announcing its plan to publicly issue 57 million shares, which will account for 13.67% of the company's total share capital after the issuance.

The initial strategic placement for this offering is set at 11.4 million shares, representing 20% of the total issuance.

The special asset management plan established for the participation of the company's senior management and core employees in this strategic placement has an initial allocation of 5.7 million shares, accounting for 10% of the total offering, with a subscription amount not exceeding 105 million yuan.

The underwriter will arrange for its related subsidiary, China CICC Wealth Securities Limited, to participate in the strategic placement of this offering, with an initial expected allocation of 2.85 million shares, representing 5% of the total issuance and a subscription amount not exceeding 40 million yuan.

The preliminary inquiry date for this offering is January 21, 2026, and the subscription date is January 26, 2026.

The company is a national high-tech enterprise focused on the research, development, production, and sales of innovative medical devices for the precision diagnosis and treatment of cardiovascular diseases, dedicated to creating transformative precision solutions for cardiovascular disease management.

The company's core product, the intravascular ultrasound (IVUS) diagnostic system, is China's first independently innovated, domestically produced 60MHz high-definition, high-speed IVUS product approved by the National Medical Products Administration.

Its other core product, the fractional flow reserve (FFR) measurement system, is the first domestically produced product approved by the NMPA in the gold-standard FFR field.

Both of these flagship products have entered the National Special Review Procedure for Innovative Medical Devices and are poised to revolutionize the clinical practice of precision-guided percutaneous coronary intervention (PCI) procedures.

The company's net profit attributable to owners of the parent company from 2022 to the first half of 2025 was as follows: -290 million yuan, -140 million yuan, -43.5962 million yuan, and 49.4496 million yuan, respectively.

The company forecasts its net profit attributable to owners of the parent company for the full year 2025 to be between 78 million yuan and 88 million yuan, representing a significant year-on-year increase of 278.91% to 301.85%.

After deducting issuance expenses, the net proceeds from this offering will be allocated, in order of priority, to the following projects: the Construction Project for the Industrialization Base of Interventional Medical Devices, the R&D Project for Interventional Medical Devices, and supplementing working capital, with a total planned investment of 952 million yuan from the raised funds.